Laurie Clair, PA
Physician Assistant · Johnston, IANPI 1790046548
Payments from drug & device makers
Across 973 payments — averaging $301.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$223K
- Vanda Pharmaceuticals Inc.$44K
- E.r. Squibb & Sons, L.L.C.$14K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$7K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$759
- plus $4K from 19 others
What the payments were for
- Consulting fees$6,1512%
- Speaking & faculty fees$247,59584%
- Travel & lodging$23,4968%
- Food & beverage$15,6265%
- Education$1580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 435 | $222,585 |
| Vanda Pharmaceuticals Inc. | 63 | $43,698 |
| E.r. Squibb & Sons, L.L.C. | 56 | $14,172 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 81 | $6,598 |
| Otsuka America Pharmaceutical, Inc. | 95 | $1,583 |
| Teva Pharmaceuticals USA, Inc. | 42 | $759 |
| Johnson & Johnson | 36 | $693 |
| Lundbeck LLC | 43 | $643 |
| Supernus Pharmaceuticals, Inc. | 17 | $552 |
| Alkermes, Inc. | 30 | $526 |
| Axsome Therapeutics, Inc. | 19 | $325 |
| Ironshore Pharmaceuticals Inc. | 13 | $153 |
| Novo Nordisk | 7 | $117 |
| Neurocrine Biosciences, Inc. | 6 | $110 |
| MDD US Operations, LLC | 5 | $94 |
| Almatica Pharma LLC | 5 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Corium, LLC | 5 | $68 |
| Neos Therapeutics, LP | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Itamar Medical Inc | 2 | $25 |
| Lilly USA, LLC | 1 | $25 |
| Bristol Myers Squibb | 1 | $18 |
| Tris Pharma Inc | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$217,184
- Fanapt$43,131
- COBENFY$5,589
- CAPLYTA$5,475
- LYBALVI$458
- QELBREE$286
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- REXULTI$108
How this compares
$293,026 in reported general payments places this provider in the 95th percentile of 1,140 physician assistant providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 108 | $164,192 |
| Austedo XrDeutetrabenazine | 17 | $131,661 |
| CaplytaLumateperone Tosylate | 47 | $80,373 |
| RexultiBrexpiprazole | 46 | $75,934 |
| AuvelityDextromethorphan Hbr/Bupropion | 34 | $49,954 |
| TrintellixVortioxetine Hydrobromide | 34 | $19,410 |
| PristiqDesvenlafaxine Succinate | 14 | $10,224 |
| Lurasidone Hcl | 23 | $6,612 |
| Lamotrigine ErLamotrigine | 12 | $4,557 |
| Quetiapine Fumarate | 154 | $4,196 |
| Divalproex Sodium ErDivalproex Sodium | 120 | $3,587 |
| Duloxetine Hcl | 255 | $3,394 |
| Aripiprazole | 85 | $3,112 |
| Acamprosate Calcium | 12 | $2,312 |
| Bupropion XlBupropion Hcl | 161 | $2,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $222,585 | $164,192108 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $759 | $131,66117 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $6,598 | $80,37347 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,583 | $75,93446 claims |
| Axsome Therapeutics, Inc.Auvelity | $325 | $49,95434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $85 | $19,41034 claims |
| Lilly USA, LLCOlanzapine | $25 | $2,05685 claims |
| Almatica Pharma LLCSertraline Hcl | $88 | $74663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,140 physician assistant providers in Iowa.
Other physician assistant in Johnston
- Jayson GesulgaUrbandale$878K
- Katherine LemAmes$224K
- Laura CunninghamWest Des Moines$128K
- Michon LeddyClive$73K
- Kyle HawkinsIowa City$42K
- Andrew MetzgerIowa City$37K
- Myrl HolidaIowa City$37K
- Kelly MerchieDavenport$15K
- Kathleen DuffyClive$13K
- Marie KresseClive$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.